Non‐invasive prenatal testing suggesting a maternal malignancy: What do we tell the prospective parents in Belgium?

Lore Lannoo,Liesbeth Lenaerts,Kris Van Den Bogaert,Huiwen Che,Nathalie Brison,Koen Devriendt,Frédéric Amant,Joris Robert Vermeesch,Kristel Van Calsteren
DOI: https://doi.org/10.1002/pd.6031
2021-08-26
Prenatal Diagnosis
Abstract:Cancer is diagnosed in 1 in 1000 to 1500 pregnancies. Most frequently encountered malignancies during pregnancy are breast cancer, hematological cancer, cervical cancer and malignant melanoma. Maternal cancer is associated with an increased risk of IUGR and preterm labor, especially in patients with systemic disease or those receiving chemotherapy during pregnancy, requiring a high-risk obstetrical follow-up.Fetal aneuploidy screening by non-invasive prenatal testing (NIPT) can lead to the incidental identification of copy number alterations derived from non-fetal cell-free DNA (cfDNA), as seen in certain cases of maternal malignancy. The identification of tumor-derived cfDNA requires further clinical, biochemical, radiographic and histological investigations to confirm the diagnosis. In such cases, reliable risk estimation for fetal trisomy 21, 18 and 13 is impossible. Therefore, invasive testing should be offered when ultrasonographic screening reveals an increased risk for chromosomal anomalies, or when a more accurate test is desired. When the fetal karyotype is normal, long term implications for the fetus refer to the consequences of the maternal disease and treatment during pregnancy.This article is protected by copyright. All rights reserved.
genetics & heredity,obstetrics & gynecology
What problem does this paper attempt to address?